Clinical Trial Notifications Triggered by Artificial Intelligence-Detected Cancer Progression: A Randomized Trial.

Journal: JAMA network open
PMID: 40257799

Abstract

IMPORTANCE: Historically, fewer than 10% of adults with cancer have enrolled in clinical trials. Computational tools have been developed to match patients to trials, but these tools are relevant only when patients need new treatment.

Authors

  • Tali Mazor
    Knowledge Systems Group, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Karim S Farhat
    Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Pavel Trukhanov
    Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA.
  • James Lindsay
    Knowledge Systems Group, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Matthew Galvin
    Knowledge Systems Group, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Emily Mallaber
    Knowledge Systems Group, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Morgan A Paul
    Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA.
  • Michael J Hassett
    Debra P. Ritzwoller, PhD, Institute for Health Research, Kaiser Permanente Colorado, Aurora, CO; Michael J. Hassett, MD, MPH, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, Harvard Medical School, Boston, MA; and Hajime Uno, PhD, Harvard Medical School, Boston, MA.
  • Deborah Schrag
    Memorial-Sloan Kettering Cancer Center, New York, USA.
  • Ethan Cerami
    Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Kenneth L Kehl
    Department of Medicine, Dana-Farber Cancer Institute, Boston, MA, 02215, United States.

Keywords

External Resources

Popular Topics
Recent Journals